Combining immune checkpoint inhibitors with denosumab: a new era in repurposing denosumab in oncology?

Combining immune checkpoint inhibitors with denosumab: a new era in repurposing denosumab in oncology? J BUON. 2020 Jan-Feb;25(1):1-14 Authors: V Deligiorgi M, Panayiotidis MI, Trafalis DT Abstract The designation of immune checkpoint inhibitors (ICPi) as scientific breakthrough of the year 2013 marked a turning point in cancer therapeutics, unleashing the host immune system against tumors. ICPi block the cytotoxic T lymphocyte antigen 4 (CTLA-4), the programmed cell death protein (PD) 1 (PD-1), and the ligand of the latter (PD-L1) ‒the landmark immune checkpoints‒abrogating the escape of cancer cells from immunosurveillance. Despite the durable antitumor response elicited by ICPi in an expanding list of cancer types and a substantial fraction of patients, the resistance to this modality ‒primary and acquired‒ has inspired research on combinational regimens to reinvigorate immunosurveillance in immune-refractory tumors. Besides various combinations of ICPi with other ICPi, targeted therapies, chemotherapy, and radiation, emphasis is placed on identification of novel partners of ICPi. Scientists capitalize on repurposing already-approved drugs to overcome τhe diminishing efficiency of commercial drug research and development. Denosumab, a human monoclonal immunoglobulin antibody inhibiting receptor activator of nuclear factor kappa-B ligand (RANKL), is excellent candidate for repurposing in oncology, given its anticancer pote...
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research